TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05980806: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Sponsor: Karyopharm Therapeutics Inc · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 58 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT05980806 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05980806 Rescue Dossier →